> Details

Leppä, Sirpa; Jørgensen, Judit; Tierens, Anne; Meriranta, Leo; Østlie, Ingunn; de Nully Brown, Peter; Fagerli, Unn-Merete; Larsen, Thomas Stauffer; Mannisto, Susanna; Munksgaard, Lars; Maisenhölder, Martin; Vasala, Kaija; Meyer, Peter; Jerkeman, Mats; Björkholm, Magnus; Fluge, Øystein; Jyrkkiö, Sirkku; Liestøl, Knut; Ralfkiaer, Elisabeth; Spetalen, Signe; Beiske, Klaus; Karjalainen-Lindsberg, Marja-Liisa; Holte, Harald

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
  • Contributor: Leppä, Sirpa; Jørgensen, Judit; Tierens, Anne; Meriranta, Leo; Østlie, Ingunn; de Nully Brown, Peter; Fagerli, Unn-Merete; Larsen, Thomas Stauffer; Mannisto, Susanna; Munksgaard, Lars; Maisenhölder, Martin; Vasala, Kaija; Meyer, Peter; Jerkeman, Mats; Björkholm, Magnus; Fluge, Øystein; Jyrkkiö, Sirkku; Liestøl, Knut; Ralfkiaer, Elisabeth; Spetalen, Signe; Beiske, Klaus; Karjalainen-Lindsberg, Marja-Liisa; Holte, Harald
  • Published: American Society of Hematology, 2020
  • Published in: Blood Advances, 4 (2020) 9, Seite 1906-1915
  • Language: English
  • DOI: 10.1182/bloodadvances.2020001518
  • ISSN: 2473-9529; 2473-9537
  • Origination:
  • Footnote:
  • Description: Abstract Survival of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and the risk of central nervous system (CNS) progression is relatively high. We conducted a phase 2 trial in 139 patients aged 18 to 64 years who had primary DLBCL with an age-adjusted International Prognostic Index (aaIPI) score of 2 to 3 or site-specific risk factors for CNS recurrence. The goal was to assess whether a dose-dense immunochemotherapy with early systemic CNS prophylaxis improves the outcome and reduces the incidence of CNS events. Treatment consisted of 2 courses of high-dose methotrexate in combination with biweekly rituximab (R), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-14), followed by 4 courses of R-CHOP-14 with etoposide (R-CHOEP) and 1 course of high-dose cytarabine with R. In addition, liposomal cytarabine was administered intrathecally at courses 1, 3, and 5. Coprimary endpoints were failure-free survival and CNS progression rates. Thirty-six (26%) patients experienced treatment failure. Progression occurred in 23 (16%) patients, including three (2.2%) CNS events. At 5 years of median follow-up, failure-free survival, overall survival, and CNS progression rates were 74%, 83%, and 2.3%, respectively. Treatment reduced the risk of progression compared with our previous trial, in which systemic CNS prophylaxis was given after 6 courses of biweekly R-CHOEP (hazard ratio, 0.49; 95% CI, 0.31-0.77; P = .002) and overcame the adverse impact of an aaIPI score of 3 on survival. In addition, outcome of the patients with BCL2/MYC double-hit lymphomas was comparable to the patients without the rearrangements. The results are encouraging, with a low toxic death rate, low number of CNS events, and favorable survival rates. This trial was registered at www.clinicaltrials.gov as #NCT01325194.
  • Access State: Open Access